CureVac NV Q4 2021 Earnings Call Summary - Thomson StreetEvents

CureVac NV Q4 2021 Earnings Call Summary

CureVac NV Q4 2021 Earnings Call Summary - Thomson StreetEvents
CureVac NV Q4 2021 Earnings Call Summary
Published Apr 28, 2022
13 pages (7622 words) — Published Apr 28, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

  
Brief Excerpt:

...A. Highlights: CVAC made significant progress over past several months. 1. 2. Expanding solid product development pipeline, broad technology platform and robust manufacturing capacities to strengthen competitive position within RNA field as central player, with key developments in these three areas, including: In Prophylactic Vaccines, successfully conducting and executing on infectious disease and dedicated COVID-19 programs in collaboration with partner GSK. a. b. Extending technology platform into multivalent and modified mRNA approaches to identify highly differentiated vaccine candidates. c. Together with GSK, advanced vaccine candidates for COVID-19 and influenza respectively into Phase 1 testing, which Co. believes will establish clinical value of improved second generation mRNA backbone. These first two studies are investigating unmodified candidates. i. ii. Two additional studies for these candidates and indications with modified candidates will be initiated later this year. d....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
CureVac NV
Ticker
CVAC.OQ
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Congrats on the progress. And maybe on the COVID-19 vaccine, on Slide 11, I think you showed some preclinical results on a multivalent vaccine in the mouse model. I'm still looking at the beta/delta bivalent against Delta versus Omicron is actually more immunogenic against the Omicron than Delta. Why is that? Any hypothesis in terms of the scientific that what's happening there? And then broadly on the COVID front, I want to get your thoughts around how you want to go about the developing Omicron monovalent vaccine versus potentially bivalent or multivalent vaccine going forward? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 28, 2022 / 1:00PM, CVAC.OQ - Q4 2021 CureVac NV Earnings Call

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Great. Just a follow-up on the German government contract or tender contract there. For the 80 million doses, is that just the COVID or does it specify any virus types? It could be other flu or other things. Can you clarify that?

Table Of Contents

CureVac NV Annual Shareholders Meeting Transcript – 2022-06-22 – US$ 54.00 – Edited Transcript of CVAC.OQ shareholder or annual meeting 22-Jun-22 12:00pm GMT

CureVac NV at JMP Securities Life Sciences Conference Transcript – 2022-06-15 – US$ 54.00 – Edited Transcript of CVAC.OQ presentation 15-Jun-22 1:30pm GMT

CureVac NV at Jefferies Healthcare Conference Transcript – 2022-06-09 – US$ 54.00 – Edited Transcript of CVAC.OQ presentation 9-Jun-22 1:30pm GMT

CureVac NV at Bank of America Healthcare Conference Transcript – 2022-05-10 – US$ 54.00 – Edited Transcript of CVAC.OQ presentation 10-May-22 3:00pm GMT

CureVac NV Q4 2021 Earnings Call Transcript – 2022-04-28 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Summary – 2021-11-19 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Transcript – 2021-11-19 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary – 2021-10-12 – US$ 54.00 – Edited Brief of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript – 2021-10-12 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript – 2021-07-01 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 1-Jul-21 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "CureVac NV Q4 2021 Earnings Call Summary" Apr 28, 2022. Alacra Store. May 02, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2021-CureVac-NV-Earnings-Call-B15189095>
  
APA:
Thomson StreetEvents. (2022). CureVac NV Q4 2021 Earnings Call Summary Apr 28, 2022. New York, NY: Alacra Store. Retrieved May 02, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2021-CureVac-NV-Earnings-Call-B15189095>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.